NO20072435L - CGRP-reseptorantagonister - Google Patents

CGRP-reseptorantagonister

Info

Publication number: NO20072435L
Authority: NO; Norway
Prior art keywords: receptor antagonists; cgrp receptor; cgrp; compounds; diseases
Prior art date: 2004-10-13

Application number

NO20072435A

Other languages

English (en)

Norwegian (no)

Inventor

Christopher S Burgey

Theresa M Williams

Zhengwu J Deng

Diem N Nguyen

Daniel V Paone

Anthony W Shaw

Joseph P Vacca

Harold G Selnick

Craig M Potteiger

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-13

Filing date

2007-05-11

Publication date

2007-07-12

2007-05-11 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2007-07-12 Publication of NO20072435L publication Critical patent/NO20072435L/no

Links

108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title abstract 2
102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 2
102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract 1
208000006561 Cluster Headache Diseases 0.000 abstract 1
206010019233 Headaches Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
208000018912 cluster headache syndrome Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
231100000869 headache Toxicity 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Addiction (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

NO20072435A 2004-10-13 2007-05-11 CGRP-reseptorantagonister NO20072435L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US61845104P	2004-10-13	2004-10-13
US68383705P	2005-05-24	2005-05-24
PCT/US2005/036763 WO2006044504A1 (en)	2004-10-13	2005-10-12	Cgrp receptor antagonists

Publications (1)

Publication Number	Publication Date
NO20072435L true NO20072435L (no)	2007-07-12

Family

ID=35705270

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20072435A NO20072435L (no)	2004-10-13	2007-05-11	CGRP-reseptorantagonister

Country Status (14)

Country	Link
US (1)	US8039460B2 (de)
EP (1)	EP1802637B1 (de)
JP (1)	JP4913061B2 (de)
KR (1)	KR20070062997A (de)
AT (1)	ATE411323T1 (de)
AU (1)	AU2005295729B2 (de)
BR (1)	BRPI0517418A (de)
CA (1)	CA2583536A1 (de)
DE (1)	DE602005010463D1 (de)
IL (1)	IL182317A0 (de)
MX (1)	MX2007004393A (de)
NO (1)	NO20072435L (de)
RU (1)	RU2007117741A (de)
WO (1)	WO2006044504A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006041830A2 (en) *	2004-10-07	2006-04-20	Merck & Co., Inc.	Cgrp receptor antagonists
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
WO2007130927A2 (en)	2006-05-02	2007-11-15	Bristol-Myers Squibb Company	Condensed tricyclic compounds as cgrp-receptor antagonists
US7470680B2 (en)	2006-05-03	2008-12-30	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
BRPI0711352A2 (pt)	2006-05-09	2011-09-27	Merck & Co Inc	composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular
KR20150081370A (ko)	2006-07-10	2015-07-13	파이온 유케이 리미티드	속효형 벤조디아제핀 염 및 이의 중합체 형태
GB0712392D0 (en) *	2007-06-26	2007-08-01	Glaxo Group Ltd	Novel compounds
GB0725103D0 (en) *	2007-12-21	2008-01-30	Glaxo Group Ltd	Novel compounds
WO2009105348A1 (en) *	2008-02-19	2009-08-27	Merck & Co., Inc.	Imidazobenzazepine cgrp receptor antagonists
US8044043B2 (en) *	2008-04-11	2011-10-25	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8715715B2 (en)	2008-11-03	2014-05-06	Nal Pharmaceuticals Ltd.	Dosage form for insertion into the mouth
US8952014B2 (en)	2008-12-19	2015-02-10	Boehringer Ingelheim International Gmbh	Pyrimidine derivatives which are CGRP—antagonists
WO2011029043A1 (en)	2009-09-04	2011-03-10	Biogen Idec Ma Inc.	Heteroaryl btk inhibitors
EP2305647A1 (de)	2009-09-18	2011-04-06	PAION UK Limited	Verfahren zur Herstellung von 3-[(4S)-8-brom-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propionsäuremethylester oder das Benzensulfonatsalz davon und in diesem Prozess nützliche Verbindungen
US8314117B2 (en) *	2009-10-14	2012-11-20	Bristol-Myers Squibb Company	CGRP receptor antagonists
WO2012058645A1 (en) *	2010-10-29	2012-05-03	Biogen Idec Ma Inc.	Heterocyclic tyrosine kinase inhibitors
EP2450039A1 (de)	2010-11-08	2012-05-09	PAION UK Ltd.	Dosierschema zur Sedierung mit CNS 7056 (Remimazolam)
WO2012087777A1 (en) *	2010-12-22	2012-06-28	Merck Sharp & Dohme Corp.	Fused heterocyclic indane carboxamide cgrp receptor antagonists
US9067941B2 (en)	2010-12-22	2015-06-30	Merck Sharp & Dohme Corp.	Fused heterocyclic azaindane carboxamide CGRP receptor antagonists
WO2013055793A1 (en)	2011-10-12	2013-04-18	University Of Pittsburg-Of The Commonwealth System Of Higher Education	Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
HRP20171620T1 (hr)	2012-02-27	2017-12-01	Bristol-Myers Squibb Company	N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol
AR094963A1 (es)	2013-03-04	2015-09-09	Ono Pharmaceutical Co	Reacción de oxidación excelente en el índice de conversión
EP3046561B1 (de)	2013-09-20	2023-02-22	University of Pittsburgh - Of the Commonwealth System of Higher Education	Verbindungen zur behandlung von prostatakrebs
US20160257657A1 (en)	2013-09-20	2016-09-08	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
GB201417707D0 (en)	2014-10-07	2014-11-19	Viral Ltd	Pharmaceutical compounds
GB201519194D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP receptor antagonists
GB201519195D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519196D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
EP3377493B1 (de)	2015-11-20	2020-04-08	Forma Therapeutics, Inc.	Purinone als ubiquitinspezifische protease-1-inhibitoren
SG10201913587WA (en) *	2016-02-05	2020-02-27	Denali Therapeutics Inc	Inhibitors of receptor-interacting protein kinase 1
US10980806B2 (en)	2016-03-24	2021-04-20	University of Pittsburgh—of the Commonwealth System of Higher Education	Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
DK3552017T3 (da)	2016-12-09	2022-05-16	Denali Therapeutics Inc	Forbindelser, der er anvendelige som ripk1-inhibitorer
EP3366286A1 (de)	2017-02-22	2018-08-29	Johannes Keller	Verbindungen zur behandlung von sepsis
AU2018334290A1 (en)	2017-09-18	2020-04-02	Goldfinch Bio, Inc.	Pyridazinones and methods of use thereof
CN108341821B (zh) *	2018-04-10	2020-10-27	千辉药业（安徽）有限责任公司	一种盐酸依匹斯汀的合成方法
IL281438B2 (en)	2018-09-18	2023-12-01	Goldfinch Bio Inc	Pyridazinones and methods of use thereof
IL286481B2 (en)	2019-03-20	2025-12-01	Goldfinch Bio Inc	Pyridazinones and methods of use thereof
MX2021012310A (es)	2019-04-11	2021-11-12	Goldfinch Bio Inc	Formulación de secado por aspersión de un inhibidor de trpc5 de piridazinona.
GB201908420D0 (en) *	2019-06-12	2019-07-24	Heptares Therapeutics Ltd	Cgrp antagonist compounds
GB201908430D0 (en)	2019-06-12	2019-07-24	Heptares Therapeutics Ltd	Cgrp antagonist compounds
WO2021005493A1 (en) *	2019-07-05	2021-01-14	Allergan Pharmaceuticals International Limited	Cgrp antagonists and botulinum toxins for the treatment of inflammatory and neurologic disorders
US20210121541A1 (en) *	2019-07-05	2021-04-29	Allergan Pharmaceuticals International Limited	CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
WO2022081514A1 (en) *	2020-10-12	2022-04-21	The Regents Of The University Of Michigan	Synthesis of egfr modulators
WO2023137035A1 (en)	2022-01-12	2023-07-20	Denali Therapeutics Inc.	Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000018764A1 (en)	1998-09-30	2000-04-06	Merck Sharp & Dohme Limited	Benzimidazolinyl piperidines as cgrp ligands
DK1539766T3 (en) *	2002-06-05	2017-04-03	Bristol Myers Squibb Co	CALCITONIN GEN-RELATED PEPTIDE RECEPTOR ANTAGONISTS

2005
- 2005-10-12 BR BRPI0517418-0A patent/BRPI0517418A/pt not_active Application Discontinuation
- 2005-10-12 AU AU2005295729A patent/AU2005295729B2/en not_active Ceased
- 2005-10-12 KR KR1020077008363A patent/KR20070062997A/ko not_active Withdrawn
- 2005-10-12 CA CA002583536A patent/CA2583536A1/en not_active Abandoned
- 2005-10-12 DE DE602005010463T patent/DE602005010463D1/de not_active Expired - Lifetime
- 2005-10-12 AT AT05804366T patent/ATE411323T1/de not_active IP Right Cessation
- 2005-10-12 US US11/665,523 patent/US8039460B2/en active Active
- 2005-10-12 RU RU2007117741/04A patent/RU2007117741A/ru not_active Application Discontinuation
- 2005-10-12 EP EP05804366A patent/EP1802637B1/de not_active Expired - Lifetime
- 2005-10-12 JP JP2007536866A patent/JP4913061B2/ja not_active Expired - Fee Related
- 2005-10-12 MX MX2007004393A patent/MX2007004393A/es not_active Application Discontinuation
- 2005-10-12 WO PCT/US2005/036763 patent/WO2006044504A1/en not_active Ceased
2007
- 2007-03-29 IL IL182317A patent/IL182317A0/en unknown
- 2007-05-11 NO NO20072435A patent/NO20072435L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MX2007004393A (es)	2007-04-25
JP2008515991A (ja)	2008-05-15
RU2007117741A (ru)	2008-11-20
ATE411323T1 (de)	2008-10-15
EP1802637A1 (de)	2007-07-04
WO2006044504A8 (en)	2006-06-08
IL182317A0 (en)	2007-07-24
US8039460B2 (en)	2011-10-18
AU2005295729B2 (en)	2011-07-14
CA2583536A1 (en)	2006-04-27
AU2005295729A1 (en)	2006-04-27
EP1802637B1 (de)	2008-10-15
KR20070062997A (ko)	2007-06-18
US20080113966A1 (en)	2008-05-15
WO2006044504A1 (en)	2006-04-27
JP4913061B2 (ja)	2012-04-11
DE602005010463D1 (de)	2008-11-27
BRPI0517418A (pt)	2008-10-07

Legal Events

Date	Code	Title	Description
2009-05-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
ATE411323T1 (de)	2008-10-15	Cgrp-rezeptorantagonisten
ATE466860T1 (de)	2010-05-15	Cgrp-rezeptorantagonisten
DE602005020655D1 (de)	2010-05-27	Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
ATE537170T1 (de)	2011-12-15	Cgrp-rezeptorantagonisten
DE602004013563D1 (de)	2008-06-19	Rantagonisten
TW200505903A (en)	2005-02-16	CGRP receptor antagonists
ATE516803T1 (de)	2011-08-15	Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
EP1606286A4 (de)	2008-08-13	Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten
ATE535514T1 (de)	2011-12-15	Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
ATE464305T1 (de)	2010-04-15	Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
EP1794133A4 (de)	2010-01-27	Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
WO2005000807A3 (en)	2006-01-05	Benzodiazepine cgrp receptor antagonists
ATE503755T1 (de)	2011-04-15	Cgrp-rezeptorantagonisten
ATE463245T1 (de)	2010-04-15	Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
ATE518852T1 (de)	2011-08-15	Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
WO2006041830A3 (en)	2006-06-01	Cgrp receptor antagonists
WO2007016087A3 (en)	2007-06-21	Heterocyclic benzodiazepine cgrp receptor antagonists
ATE507880T1 (de)	2011-05-15	Cgrp-rezeptorantagonisten
ATE466853T1 (de)	2010-05-15	Cgrp-rezeptorantagonisten